The dosing your patients need—the control you want

All patients who are receiving long-acting opioid therapy should be monitored closely. It is imperative that the prescribers clinical judgment be utilized on each individual case.

Patients 65 years of age or older, patients with mild hepatic impairment, and patients with moderate to severe renal impairment, have an increase in oxymorphone bioavailability. For these patients on prior opioid therapy, start at 50% of the starting dose for a younger patient or a patient with normal hepatic or renal function and titrate slowly.

All patients who are receiving long-acting opioid therapy should be monitored closely. It is imperative that the prescribers clinical judgment be utilized on each individual case.